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Abstract
The transforming growth factor-b (TGF-b) signaling pathway is involved in a diverse array of cellular processes responsible
for tumorigenesis. In this case-control study, we applied a pathway-based approach to evaluate single-nucleotide
polymorphisms (SNPs) in the TGF-b signaling pathway as predictors of ovarian cancer risk. We systematically genotyped 218
SNPs from 21 genes in the TGF-b signaling pathway in 417 ovarian cancer cases and 417 matched control subjects. We
analyzed the associations of these SNPs with ovarian cancer risk, performed haplotype analysis and identified potential
cumulative effects of genetic variants. We also performed analysis to identify higher-order gene-gene interactions
influencing ovarian cancer risk. Individual SNP analysis showed that the most significant SNP was SMAD6: rs4147407, with an
adjusted odds ratio (OR) of 1.60 (95% confidence interval [CI], 1.14–2.24, P=0.0066). Cumulative genotype analysis of 13
SNPs with significant main effects exhibited a clear dose-response trend of escalating risk with increasing number of
unfavorable genotypes. In gene-based analysis, SMAD6 was identified as the most significant gene associated with ovarian
cancer risk. Haplotype analysis further revealed that two haplotype blocks within SMAD6 were significantly associated with
decreased ovarian cancer risk, as compared to the most common haplotype. Gene-gene interaction analysis further
categorized the study population into subgroups with different ovarian cancer risk. Our findings suggest that genetic
variants in the TGF-b signaling pathway are associated with ovarian cancer risk and may facilitate the identification of high-
risk subgroups in the general population.
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Introduction
Ovarian cancer is the leading cause of death from gynecologic
cancer among women in the United States, with an estimated
21,880 new cases and 13,850 deaths in 2010 [1]. Because the
disease is mostly symptomless in early stages and there are
currently no effective screening methods, 75% of women present
with advanced-stage disease (stage III or IV). The 5-year survival
rate of advanced-stage disease is only around 30% [2]. The
etiology of ovarian cancer remains largely unknown, although
hormonal factors, inflammation, and wound healing are thought
to play important roles [3].
Ovarian cancer is a multifactorial disease and genetic suscepti-
bilityhas been suggested inprevious studies. For example,mutations
in BRCA1, BRCA2, MLH1,a n dMSH2 were found to account for
approximately 50% of familial ovarian cancers [4,5]. However,
there are compelling evidence suggesting that common genetic
variants contribute to ovarian cancer susceptibility [6,7]. Recently,
genome-wide association studies (GWAs) have identified several
common susceptibility alleles in four loci showing strong associa-
tions, but as most SNPs identified in GWAs, the associations are
usuallylowinmagnitudewithmostofthe ORslessthan1.3[8,9,10].
Duetotheheterogeneousandmultigenicnatureofovariancancer,it
is unlikely that any single SNP will be sufficient to confer disease risk.
A comprehensive pathway-based analysis that focuses on evaluating
the cumulative effects of a panel of SNPs would be more powerful to
pinpoint the susceptibility genes and polymorphisms.
The transforming growth factor-b (TGF-b) pathway, including
TGF-bs, bone morphogenetic proteins (BMPs), activins, and related
proteins, is involved in a diverse array of cellular processes, including
cell proliferation, morphogenesis, migration, extracellular matrix
production, and apoptosis. Alteration of TGF-bsuperfamilysignaling
has been implicated in various human pathologies, including cancer,
developmental disorders, cardiovascular and autoimmune diseases
[11,12,13]. Experimental data have shown that more than 75% of
humanovariancancersexhibitresistancetoTGF-bsignaling[14,15],
suggestingthat diminished TGF-bresponsivenessis akey event inthis
disease. In normal ovarian surface epithelial cells, autocrine growth
inhibition is maintained by TGF-b [16], but tumor cells escape the
antiproliferative effects of TGF-b by acquiring mutations in the
components of the signaling pathways or by selectively disrupting
TGF-b. Mutations and deletions of Smad genes in the TGF-b
signaling pathway often lead to unstable protein products that are
rapidly degraded after ubiquitination and shift the equilibrium of the
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reported the presence of some common genetic variations in the
TGF-b signaling pathway to be related to ovarian carcinogenesis,
such as TGFB1: rs56361919 in 23% of ovarian cancer cases [17]. In
addition, mutations and/or alterations in the expression of TGF-b
receptors and loss of SMAD4 are frequently detected in human
ovarian tumors [18].
Given the critical role of the TGF-b pathway in maintaining
proper cellular function and the disruption of this pathway in
ovarian cancer, it is possible that common genetic variations in this
Table 1. Associations between TGF-b Pathway SNPs and ovarian cancer risk.
Gene SNP Genotype (case/control) OR (95% CI)* Model** P
Bootstrap
P,.05
WW (n/n) WV (n/n) VV (n/n) MAF
BMP2 rs235757 174/157 198/192 45/68 0.35/0.39 0.64 (0.42–0.95) REC 0.029 96
INHA rs7588807 107/82 216/241 94/94 0.48/0.51 0.70 (0.50–0.98) DOM 0.035 64
INHBC rs2228225 131/171 203/174 83/72 0.44/0.38 1.48 (1.11–1.99) DOM 0.008 100
rs4760259 165/199 199/171 53/47 0.37/0.32 1.39 (1.06–1.84) DOM 0.019 95
SMAD1 rs11724777 160/155 200/177 57/85 0.38/0.42 0.63 (0.43–0.91) REC 0.014 100
rs6537355 340/319 69/93 8/4 0.10/0.12 0.69 (0.49–0.98) DOM 0.036 11
SMAD2 rs1792689 328/301 87/105 2/11 0.11/0.15 0.69 (0.50–0.95) DOM 0.024 85
rs1792658 256/228 138/166 19/19 0.21/0.25 0.75 (0.56–0.99) DOM 0.043 55
SMAD3 rs10152307 243/206 140/179 34/32 0.25/0.29 0.72 (0.54–0.95) DOM 0.019 100
rs4776892 269/244 123/155 25/18 0.21/0.23 0.73 (0.55–0.98) DOM 0.035 28
rs7183244 192/160 167/186 58/71 0.34/0.39 0.74 (0.56–0.98) DOM 0.035 88
SMAD6 rs4147407 313/343 100/69 4/5 0.13/0.09 1.60 (1.14–2.24) DOM 0.007 100
rs4075546 185/152 185/199 47/66 0.33/0.40 0.77 (0.63–0.94) ADD 9.9610
23 100
rs16953584 258/235 144/150 15/31 0.21/0.25 0.45 (0.24–0.87) REC 0.016 95
rs2053424 139/166 212/182 66/68 0.41/0.38 1.43 (1.07–1.92) DOM 0.017 51
rs5014202 278/251 125/145 14/21 0.18/0.22 0.78 (0.61–0.99) ADD 0.040 67
rs4776318 140/116 198/201 79/100 0.43/0.48 0.82 (0.68–1.00) ADD 0.047 83
SMAD7 rs17186485 370/346 47/67 0/4 0.06/0.09 0.63 (0.42–0.93) DOM 0.021 94
rs3736242 229/259 168/137 18/21 0.25/0.21 1.37 (1.03–1.81) DOM 0.029 51
rs7238442 124/120 206/193 84/104 0.45/0.48 0.70 (0.50–0.99) REC 0.041 2
SMAD9 rs648206 118/127 195/210 104/80 0.48/0.44 1.45 (1.04–2.02) REC 0.029 61
rs576434 141/115 191/213 85/89 0.43/0.47 0.74 (0.55–0.99) DOM 0.046 61
TGFB1 rs8179181 269/236 119/158 24/21 0.20/0.24 0.72 (0.54–0.96) DOM 0.025 100
Note: Significant SNPs after internal validation by bootstrapping analysis (significant in $80 runs among 100 runs) are in boldface. WW, homozygous wild-type
genotype; WV, heterozygous variant genotype; VV, homozygous variant genotype.
Abbreviations: DOM, dominant model (WW vs. [WV and VV]); REC, recessive model ([WW and WV] vs. VV); ADD, additive model (P for trend with increasing number of
variant [V] alleles); MAF, minor allele frequency.
*Adjusted by age and ethnicity by unconditional logistic regression.
**The model with the most significant P value was defined as the best model for each SNP.
doi:10.1371/journal.pone.0025559.t001
Table 2. Cumulative analysis of significant SNPs in TGF-b pathway on ovarian cancer risk.
No. of unfavorable genotypes
Case/control (number of
case/number of control) OR (95% CI)* P Bootstrapped95% CI
2–4 31/9 1 (Ref.)
5–7 174/122 2.45 (1.12–5.33) 0.02424 1.13–6.20
8–10 177/220 4.42 (2.04–9.57) 0.00017 2.07–11.18
11–13 32/61 6.75 (2.83–16.12) 1.68610
25 2.78–18.47
P for trend 1.67610
28
Note: Unfavorable genotypes: BMP2: rs235757 GG; INHBC: rs2228225 AG+GG and rs4760259 (CT+TT); SMAD1: rs11724777 TT; SMAD2: rs1792689 CT+TT;
SMAD3: rs10152307 CT+TT and rs7183244 CT+TT; SMAD6: rs4147407 CT+TT, rs4075546 AG+GG, rs16953584 GG, and rs4776318 AC+CC; SMAD7: rs17186485 AG+GG;
TGFB1: rs8179181 CT+TT.
*Adjusted by age and ethnicity.
doi:10.1371/journal.pone.0025559.t002
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no molecular epidemiologic studies have been performed to
comprehensively evaluate genetic variants in this pathway with
ovarian cancer risk. In this study, we aimed to test the hypothesis
that common germline genetic variants in the TGF-b pathway are
associated with ovarian cancer risk.
Methods
Study population and data collection
The patient population has been described previously [19].
Briefly, 417 newly diagnosed and histologically confirmed ovarian
cancer patients with primary malignancy were recruited at The
University of Texas MD Anderson Cancer Center. Cases had not
received any chemotherapy or radiotherapy prior to recruitment.
There were no restrictions on recruitment in terms of age, ethnicity,
or clinical stage of disease. The 417 controls were healthy women
without prior history of cancer (except nonmelanoma skin cancer)
and identified from a large pool of control subjects enrolled in on-
going case-control studies of cancer. Controls subjects were
individuals seeing a physician for routine health checkups or
addressing health concerns at the Kelsey–Seybold Clinic. Cases and
controls were matched by age (65 years) and ethnicity.
Demographic characteristics (age and ethnicity), occupational
history, tobacco use history, medical history, family history of
cancer, and other epidemiologic data were collected for all patients
and controls. For each participant, a blood sample was collected
into heparinized tubes for lymphocyte isolation and DNA
extraction. For all cases and controls, a written informed consent
was obtained prior to participation and the donation of blood
samples. The study was approved by Institutional Review Boards
of MD Anderson and Kelsey Seybold Clinic.
SNP Selection and Genotyping
The procedures used to select SNPs of the TGF-b pathway have
been described previously [20]. Briefly, we compiled data from
Gene Ontology (http://www.geneontology.org) and a systematic
literature review to refine the gene list in the TGF-b signaling
pathway.Tagging SNPswereidentifiedfromthe HapMapdatabase
(http://www.hapmap.org) and selected using LDSelect program
(http://droog.gs.washington.edu/ldSelect.html) to separate SNPs
into bins on the basis of linkage disequilibrium. Selected tagging
SNPs have a r
2 threshold of 0.8, minor allele frequency (MAF)
greater than 0.01 in Caucasian population and are located within
10 kb upstream of transcriptional start site and 10 kb downstream
of transcriptional end site. Potentially functional SNPs (e.g., coding
SNPs and SNPs in untranslated regions, promoters, and splicing sites)
were also included. Overall, 218 SNPs in 21 genes of the TGF- b
pathway were selected along with SNPs from other cancer-related
pathways. Complete set of SNPs was sent to Illumina technical
support for custom iSelect, Infinium II BeadChip design using
proprietary program developed by Illumina. Genomic DNA was
isolated from peripheral blood lymphocytes using the QIAamp DNA
Blood Maxi kit (QIAGEN, Valencia, CA). Genotyping followed the
standard protocol of Illumina’s Infinium iSelect HD Custom
Genotyping Beadchip provided by Illumina (San Diego, CA).
BeadStudio software was used to call genotypes. All laboratory
personnel were blinded to the case-control status of the study subjects.
Table 3. Global gene P values for significant associations between common genetic variations in TGF-b signaling pathway and
ovarian cancer risk.
Gene name Number of SNPs genotyped per gene P for SNPs in gene, by model
Dominant model Additive model
SMAD6 29 .034 .064
TGFB1 6 .045 .190
SMAD7 21 .074 .147
INHBC 5 .125 .137
AMHR2 1 .188 .130
INHA 4 .208 .640
ACVR2A 3 .220 .184
SMAD2 8 .223 .264
SMAD3 49 .252 .779
SMAD1 8. 2 6 2 .050
ACVR2B 3 .374 .465
SMAD9 17 .397 .307
BMP2 14 .415 .528
ACVR1B 3 .481 .743
BMP4 5 .570 .724
NODAL 6 .580 .558
SMAD5 5 .644 .621
SMAD4 4 .810 .894
GDF1 3 .893 .962
BMP1 17 .928 .948
ACVR1C 3 .933 .878
Note: Significant P values in boldface.
doi:10.1371/journal.pone.0025559.t003
TGF-b Pathway and Ovarian Cancer Risk
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25559Statistical Analyses
The distribution of categorical variables and continuous
variables between cases and control subjects was compared by
Pearson’s x
2 test and Student’s t test, respectively. For each SNP in
this study, we tested Hardy-Weinberg equilibrium using the
goodness-of-fit x
2 test to compare the observed with the expected
frequency of genotypes in control subjects. For SNP analysis, we
tested three different genetic models, dominant model, recessive
model and additive model to identify the best-fitting model with
the smallest P value. If the percentage of the homozygous variant
genotypes was less than five in cases or controls, we only
considered the dominant model which has the highest statistical
power. Multiple logistic regression analysis was used to estimate
the odds ratios (ORs) and 95% confidence intervals (CI) while
adjusting for age and ethnicity where appropriate. For internal
validation, a bootstrap resampling method was performed 100
times on samples randomly drawn from the original data set
and a P values was obtained for the best-fitting model in each
bootstrapped sample. Cumulative effects of SNPs were assessed by
summing up the putative unfavorable genotypes showing signif-
icant association with the risk (P,0.05) in single SNP analysis and
then grouped into four categories based on the distribution
of ORs. A gene-based analysis was used to explore the associa-
tions between genes and ovarian cancer risk using the likelihood-
ratio test (LRT) as described previously [21]. Classification and
regression tree (CART) analysis was used to explore higher-order
gene-gene interactions using the Expectation-Haplotype analysis
was performed using the maximization algorithm implemented in
the HelixTree software (Golden Helix, Bozeman, MT). We also
performed 10,000 bootstrap runs to construct 95%CIs for the ORs
in cumulative genotype analysis and CART analysis. All statistical
analyses were adjusted for age, ethnicity. Statistical analysis was
performed using STATA 10.0 (College Station, TX).
Results
Subject characteristics
In this study, there were 417 cases and 417 age- and ethnicity-
matched control subjects. The mean age was 60.73 (SD: 10.36) in
cases and 60.30 (SD: 10.71) in control subjects (P=0.554). The
majority of the cases (n=339, 81.29%) and controls (n=349,
83.69%) were Caucasians. Of the cases, the majority are
diagnosed at stage III (66.5%), whose tumors are of the serous
subtype (61.3%) (Table S1).
Association between individual SNP and risk
A total of 218 SNPs from 21 genes in the TGF-b pathway were
analyzed (Table S2). Twenty-three SNPs from ten genes showed
significant associations with ovarian cancer risk at P,0.05
(Table 1). Internal validation by bootstrapping method identified
13 SNPs from eight genes showing consistent associations (i.e.
P,0.05 in 80 or more among 100 bootstrapped samples). The most
significant SNP was SMAD6: rs4147407 with subjects carrying at
least one variant allele exhibiting a 1.60-fold increased risk (95%CI,
Figure 1. The linkage disequilibrium map of genotyped SMAD6 SNPs.
doi:10.1371/journal.pone.0025559.g001
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rs4075546 was associated with decreased risk (OR, 0.77; 95%CI,
0.63–0.94, P=0.0099).
We further explored the cumulative effects of these 13 significant
genetic variants in the TGF-b pathway on ovarian cancer risk.
Comparedwith those who carriedfewer than4 unfavorable genotypes,
subjects carrying 5–7, 8–10, and 11–13 unfavorable genotypes showed
a significantly increased risk with ORs of 2.45 (95%CI, 1.12–5.33;
P=0.024), 4.42 (95%CI, 2.04–9.57; P=0.00017), and 6.75 (95%CI,
2.83–16.12; P=0.68 610
25), respectively (P for trend=1.67610
28;
Table 2).
Gene based analysis for ovarian cancer risk
Gene-based analysis identified SMAD6 and TGFB1 (P,0.05 for
all SNPs examined in each gene using the dominant or additive
model; Table 3) as genes associated with ovarian cancer risk.
SMAD6 showed the most significant association (P=.034),
suggesting that of the genes examined genetic variations in this
gene had the strongest influence on ovarian cancer risk..
Haplotype analysis of SMAD6 SNPs
As multiple SNPs in the SMAD6 gene showed significant
associations, we performed haplotype analysis for the 29 SNPs
genotyped in SMAD6. Five haplotype blocks were defined by local
linkagedisequilibrium(LD)accordingtoHaploView[22](Figure 1,
Table 4). The definition of ‘‘blocks’’ was described previously by
Gabriel et al. [23] We observed significant associations between
SMAD6 haplotypes and risk for ovarian cancer in two LD blocks,
block 1 in the 59 flanking region and block 2 in intron 5 region
(Figure 1 and Table 4). Haplotype H2 of block 1 was composed of
SNPs rs11857194-rs1470123-rs2053424, and subjects carrying only
one variant allele of rs1470123 showed a significant decrease in
association with ovarian cancer risk (OR, 0.72; 95%CI, 0.55–0.95;
P=.018) compared with those carryingthe mostcommon haplotype
of only one variant allele of rs205342. Haplotype H1 of block 2
comprised of SNPs rs16953584-rs7182227, and subjects carrying
only one variant allele of rs16953584 showed a significant 36%
reduction in risk (OR, 0.64; 95%CI, 0.44–0.92; P=.016) compared
with the most common haplotype of two wildtype alleles (Table 4)
Higher-order gene-gene interactions
CART analysis was applied to explore the higher-order
interactions between the 13 significant SNPs. As shown in Figure 2,
the tree model resulted in four terminal nodes with different risks for
ovarian cancer. The initial split was defined by INHBC: rs2228225,
indicating that this SNP is the primary factor contributing to
variations in ovarian cancer risk in the study population. The
reference node of the tree structure was composed of INHBC:
rs2228225 AA, SMAD6: rs4147407 CC, and BMP2: rs235757
AA+AG genotypes. Subjects in this node showed the lowest risk of
ovarian cancer. The high node was composed of INHBC: rs2228225
AA and SMAD6: rs4147407 CT+TT and indicated the highest risk
of ovarian cancer, with an OR of 6.33 (95%CI, 2.32–17.28;
P=.0003), suggesting that the genetic variant of SMAD6: rs4147407
was a major determinant to switch the trend of lowest risk to highest
risk of ovarian cancer (Figure 2 and Table 5).
Discussion
In this study, we systematically evaluated the associations
between a comprehensive panel of genetic variants in the TGF-b
pathway genes and ovarian cancer risk. Our results suggested that
multiple SNPs in the pathway were associated with ovarian cancer
risk. In particular, SNPs in SMAD6 showed the most significant
associations in single SNP and haplotype analyses. Further, there
was a cumulative effect of SNPs in the pathway that conferred a
significant dose-response trend with subjects carrying the highest
number of unfavorable genotypes exhibiting the greatest risk.
Results from CART analysis suggested higher-order gene-gene
interactions that further defined high vs. low risk subgroups in the
study population.
One of the major findings was the significant association of
SMAD6 polymorphisms with ovarian cancer risk. SMAD6 encodes
a protein that is localized in both nuclei and cytoplasm [24] and
works as an inhibitory Smad induced by BMPs and TGF-b signals
for an auto-inhibitory feedback mechanism in the TGF-b pathway
[25,26]. The SMAD6 gene is expressed in most human tissues,
including the ovary (Figure S1). Moreover, SMAD6 was reported
to be overexpressed in ovarian adenocarcinoma compared to
normal ovarian tissue [27], and expression of BMP-2 protein has
been shown to induce SMAD6 expression in ovarian cancer cells
and was associated with poor prognosis [28]. The function of
SMAD6 in tumorigenesis has not been well established. However,
mutations in SMAD6 have been reported in human ovarian cancer
[29]. Since TGF-b signals may function in potent tumor
suppression in normal epithelial cells and in early-stage tumors
[11], we speculated that genetic variations in SMAD6 may result in
altered gene expression or regulation of signaling function. In this
Table 4. Association between SMAD6 haplotypes and ovarian
cancer risk.
SMAD6 Control, n (%) Case, n (%)
Adjusted
OR (95% CI)* P
Block1
H0:W_W_V 318 (48.04) 344 (51.96) 1 (Ref.)
H1:W_W_W 119 (50.00) 119 (50.00) 0.85 (0.63–1.16) .303
H2:W_V_W 192 (55.33) 155 (44.67) 0.72 (0.55–0.95) .018
H3:V_V_W 205 (48.69) 216 (51.31) 0.95 (0.74–1.21) .654
Block2
H0:W_W 622 (48.56) 659 (51.44) 1 (Ref.)
H1:V_W 79 (58.96) 55 (41.04) 0.64 (0.44–0.92) .016
H2:V_V 133 (52.78) 119 (47.22) 0.85 (0.65–1.12) .247
Block3
H0:V_W 356 (48.44) 379 (51.56) 1 (Ref.)
H1:W_W 211 (53.96) 180 (46.04) 0.80 (0.62–1.03) .081
H2:W_V 265 (49.07) 275 (50.93) 0.99 (0.79–1.24) .942
Block4
H0:W_W_W 430 (50.18) 427 (49.82) 1 (Ref.)
H1:W_V_W 116 (45.85) 137 (54.15) 1.19 (0.89–1.57) .236
H2:V_V_W 74 (49.01) 77 (50.99) 1.01 (0.72–1.43) .934
H3:V_V_V 206 (52.02) 190 (47.98) 0.96 (0.75–1.22) .741
Block5
H0:W_W_W 308 (49.12) 319 (50.88) 1 (Ref.)
H1:W_W_V 120 (54.55) 100 (45.45) 0.77 (0.56–1.07) .117
H2:W_V_W 120 (47.62) 132 (52.38) 1.00 (0.75–1.35) .976
H3:V_W_V 282 (50.54) 276 (49.46) 0.94 (0.74–1.18) .575
Note: Block 1: rs11857194-rs1470123-rs2053424; Block 2: rs16953584-rs7182227;
Block 3: rs755451-rs7161970; Block 4: rs7180265–rs4776831–rs12913975;
Block 5: rs12906270–rs3934907–rs3934908.
*Adjusted by age and ethnicity.
doi:10.1371/journal.pone.0025559.t004
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and rs4776318) in SMAD6 were found to be significantly
associated with ovarian cancer risk. Among these polymorphisms,
rs4147407 was associated with increased risk, whereas rs4075546,
rs16953584, and rs4776318 were associated with decreased risk.
Haplotype analysis further identified two candidate loci of SMAD6.
Haplotype blocks located in the 59 flanking region and intron 5 of
the SMAD6 gene respectively, were both associated with decreased
risk in this study. However, none of these SNPs are located in the
coding region of SMAD6, which suggest that these significant SNPs
or the identified loci may not directly alter SMAD6 function but
may change the level of gene expression through being located in
regulatory regions or being linked to other causal SNPs to affect
gene activity. Further in vitro and in vivo functional studies are
needed to characterize the functional significance of the SMAD6
SNPs identified.
CART analysis revealed gene-gene interactions among INHBC,
SMAD6, and BMP2. In the tree model, INHBC:rs2228225 was at
the initial split, suggesting that this variant functions as the primary
risk factor for ovarian cancer. SMAD6: rs4147407 was located in
the second level of the tree structure and was shown to interact
with the INHBC: rs2228225 to influence cancer risk. Specifically,
the variant alleles of rs4147407 were associated with a 6-fold
increase in risk along with common allele of INHBC: rs2228225.
Indeed, INHBC has been identified as beta C chain of inhibin, a
hormone that can regulate cell growth and differentiation [30].
The result of CART analysis further strengthened the crucial role
of SMAD6 in influencing the risk of ovarian cancer in the study
population.
Our study has some limitations. Chance findings are possible
due to small sample size of subgroups. However, we used various
statistical methods to control for false positives. For example, we
performed bootstrapping analysis for internal validation of the
significant SNPs. Other potential limitations include the fact that
unmeasured ovarian cancer risk factors in this study (e.g. hormone
replacement use) may confound the overall association. Given that
Figure 2. CART analysis of genetic polymorphisms in the TGF-b signaling pathway and risk of ovarian cancer. ORs and 95% CIs
(in parenthesis) are presented underneath each terminal node.
doi:10.1371/journal.pone.0025559.g002
Table 5. Odds ratios of terminal nodes derived from CART analysis for ovarian cancer.
Node group Control, n (%) Case, n (%) Adjusted OR (95% CI)* P Bootstrap (95% CI)
Low risk (node1) 27 (81.82) 6 (18.18) 1 (Ref.)
Medium low risk (node 2) 115 (57.79) 84 (42.21) 3.25 (1.28–8.24) .013 1.38–11.32
Medium high risk (node 3) 246 (46.24) 286 (53.76) 5.08 (2.05–12.56) 4.0610
24 2.21–16.76
High risk (node 4) 29 (41.43) 41 (58.57) 6.33(2.32–17.28) 3.0610
24 2.42–22.14
P for trend 1.42610
25
Note: Node groups are as shown in Figure 2.
*Adjusted by age and ethnicity using unconditional logistic regression.
doi:10.1371/journal.pone.0025559.t005
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tal-driven hypothesis, this limitation may be less of a concern. As
with all case-control studies, selection bias may also confound the
identified associations. Nevertheless, MD Anderson serves as a
referral center for many cancer patients from the Kelsey Seybold
Clinics in the Houston metropolitan area; therefore our controls
are likely to represent the base population that give rise to cancer
cases.
In conclusion, our study is the first study to apply a pathway-
based approach to evaluate germline genetic variations in the
TGF-b pathway and their associations with ovarian cancer risk.
We have identified 13 polymorphisms in the TGF-b pathway
significantly associated with ovarian cancer risk. In particular,
SNPs in SMAD6 showed the most significant associations. Our
data also suggested a cumulative effect of SNPs in the pathway
that jointly influenced ovarian cancer risk, and identified higher-
order interactions that further define high vs. low risk subgroups in
the study population. Future studies are necessary to characterize
functional significance of the genetic variants we have identified, as
well as to confirm or externally validate the associations in
independent populations.
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